Investigational treatments for lung cancer, Huntington’s disease and Alzheimer's gain Innovation Passports through the Innovative Licensing and Access Pathway
What was announced
Three innovative medicines with the potential to meet unmet needs in lung cancer, Huntington’s disease and Alzheimer’s disease have been given Innovation Passports, the Medicines and Healthcare products Regulatory Agency (MHRA) announced today.
Key points, in the publisher's words
- This means they can access coordinated support throughout development through the UK’s Innovative Licensing and Access Pathway (ILAP). This is the only end-to-end access pathway in the world where developers can work, from early stages of clinical development, with the national health system, the regulator and health technology assessment bodies.
- The ILAP is designed to de-risk product development and accelerate patient access to transformative new medicines and drug-device combinations, by providing a single integrated platform for collaboration.
- Following assessment by the ILAP Selection Panel, Innovation Passports have been awarded to:
Figures in this announcement
Each line is quoted from the original. Figures are as the publisher stated them on the day.
- “Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for around 80–85% of cases.”
- “Around 50,200 people are diagnosed with lung cancer in the UK each year.”
- “An estimated 982,000 people were living with dementia in the UK in 2024, with the number expected to rise.”
Who and where
UK bodies of power
- Medicines and Healthcare products Regulatory Agency (executive agency) · more news
- National Institute for Health and Care Excellence (executive non-departmental public body) · more news
Where this sits in the 10 levels of power
Topics, as GOV.UK files them: Research and innovation in health and social care.
Receipt
- Original: https://www.gov.uk/government/news/investigational-treatments-for-lung-cancer-huntingtons-disease-and-alzheimers-gain-innovation-passports-through-the-innovative-licensing-and-access-pa
- Published 2026-11-09 09:00:04 UTC
- Read by this site 2026-11-09 09:00:43 UTC from GOV.UK
- Saved copy: receipt 11026, with its SHA-256 fingerprint
Contains public sector information licensed under the Open Government Licence v3.0.
Related official news
- MHRA sets out approach to strengthen patient and public involvement and engagement in medicines and medical device regulation
- MHRA guidance on its assessment of non-clinical data generated outside OECD system
- Clinical trials for medicines: Inclusion and Diversity Plan pilot findings published
- MHRA launches patient safety essay competition for MedSafetyWeek
- Triheptanoin (Dojolvi) approved to treat adults and children with a group of rare inherited disorders
- MHRA approves gene-editing treatment for children aged five and over with serious inherited blood disorders
- New MHRA research puts needle-free Strep A vaccine within reach
- MHRA approves deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults
More from GOV.UK
- Applications open for bass authorisations
- £40 million for GPs to keep vulnerable patients out of hospital this winter
- NRS completes largest land remediation project at Harwell
- UK Government awards £1 million to Northern Ireland community group forum
- PM call with President Stubb of Finland: 8 November 2026
- Scottish Secretary honours armed forces at Remembrance service
Also announced on 9 November 2026
- South Sudan validates new immunization guidelines to protect every child and community
- A landmark step for public health: South Sudan launches first-ever cancer registry
- WHO Delivers 24 Wheelchairs to Strengthen Rehabilitation Services During World Polio Day Commemoration in Ethiopia
- Uganda and the Democratic Republic of the Congo strengthen cross-border collaboration on health security